Hitting Refresh: Aduro CEO On Company Cuts, Pipeline Programs And Alliances
Executive Summary
Aduro Biotech announced a “strategic reset” in January 2019 that will see the Californian company center around two core pipeline programs, cut its headcount and focus on pharma partnerships. Stephen Isaacs, chair, president and CEO of the company, speaks to In Vivo about his vision for Aduro as the 2020s approach, and the challenges a smaller biotech faces when balancing multiple big pharma agreements.
You may also be interested in...
Chinook Will Soon Have $275m To Advance Kidney Disease Strategy
Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”
Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.